To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia

Vaccine and Infectious Diseases and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA;Department of Medicine, University of Washington, Seattle, WA
Department of Oncology Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2018.201897